FCPM III Services’s Vor Biopharma VOR Stock Holding History

FCPM III Services’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$73.5M	Buy	4,117,354 +500,000	+14%	+$7.05M	10.17%	3
2025 Q4	$47.3M	Buy	3,617,354 +3,237,714	+853%	+$60.3M	6.2%	6
2025 Q3	$18.5M	Buy	+379,640	New	+$15.3M	3.7%	6

Other funds holding VOR

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

FCPM III Services's VOR Position: Q1 2026 in Review

FCPM III Services increased its Vor Biopharma (VOR) stake by 14% in Q1 2026, buying an estimated $7.05M and bringing the position to 4,117,354 shares worth $73.5M. The position accounts for 10.17% of the portfolio, ranked #3.

FCPM III Services first reported a position in VOR in Q3 2025 and has held it in 3 quarters since. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

FCPM III Services held 4,117,354 shares of Vor Biopharma worth $73.5M as of Q1 2026.
FCPM III Services bought 500,000 Vor Biopharma shares in Q1 2026, an estimated $7.05M.
Vor Biopharma made up 10.17% of FCPM III Services's portfolio in Q1 2026, its #3 holding.
FCPM III Services first reported a position in Vor Biopharma in Q3 2025 and has held it in 3 quarters since.
80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on FCPM III Services's 13F filing for Q1 2026, filed 15 May 2026.